Last $22.81 USD
Change Today -0.08 / -0.35%
Volume 14.0K
FLXN On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

flexion therapeutics inc (FLXN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - $24.48
52 Week Low
05/1/14 - $11.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

flexion therapeutics inc (FLXN) Related Businessweek News

No Related Businessweek News Found

flexion therapeutics inc (FLXN) Details

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

21 Employees
Last Reported Date: 11/14/14
Founded in 2007

flexion therapeutics inc (FLXN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $437.1K
Co-Founder and Chief Medical Officer
Total Annual Compensation: $327.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $186.5K
Compensation as of Fiscal Year 2013.

flexion therapeutics inc (FLXN) Key Developments

Flexion Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 09:00 AM

Flexion Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 09:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Michael D. Clayman, Co-Founder, Chief Executive Officer, President and Director.

Flexion Therapeutics, Inc. Initiates Phase 3 Clinical Trial of FX006 in Patients with Osteoarthritis of the Knee

Flexion Therapeutics, Inc. announced dosing of the first patient in the Phase 3 clinical trial of its lead drug candidate FX006 as a treatment for pain associated with osteoarthritis (OA) of the knee. FX006 is Flexion's novel, non-opioid, sustained-release, intra-articular (IA or within the joint) formulation of triamcinolone acetonide (TCA). FX006 is designed for patients with moderate to severe OA pain and is intended to provide substantial and persistent pain relief while avoiding systemic side effects. The newly initiated randomized, double-blind Phase 3 trial will take place at about 60 centers worldwide. Approximately 450 patients will be randomized to one of three treatment groups (1:1:1) and treated with a single IA injection of either saline (placebo) or 40 mg of FX006 or 40 mg of TCA. Each patient will be evaluated for efficacy and safety at 7 outpatient visits over 24 weeks after receiving an injection. The primary objective of this study is to assess the magnitude and duration of pain relief of FX006 at 12 weeks against placebo. The secondary objectives of this study are to assess the effect of FX006 on the magnitude and duration of pain relief relative to immediate-release TCA and the effect of FX006 on function, responder status, global impressions of change, stiffness and consumption of analgesic medications relative to both controls. The current pivotal Phase 2b trial and the newly initiated Phase 3 trial are designed to provide the required data for FX006 to be submitted for regulatory approval by the FDA.

Flexion Therapeutics Seeks Acquisitions

Flexion Therapeutics, Inc. (NasdaqGM:FLXN) has filed a Follow-on Equity Offering. It may also use a portion of the net proceeds from this offering to in-license, acquire or invest in complementary businesses, technologies, products or assets.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLXN:US $22.81 USD -0.08

FLXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FLXN.
View Industry Companies

Industry Analysis


Industry Average

Valuation FLXN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLEXION THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at